Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature
Wong, M.; Sade, S.; Gilbert, M.; Klieb, H.B.E.
Dermatology Online Journal 17(5): 4
2011
ISSN/ISBN: 1087-2108 PMID: 21635826 Document Number: 648064
Dermatologic manifestations from therapy with imatinib are well known and frequently include hypopigmentation, and less commonly, hyperpigmentation. There have been few reports of oral hyperpigmentation. We present a case of palatal melanosis related to imatinib therapy for chronic myelogenous leukemia. This case is reported to add to the sparse literature concerning mucosal reactions related to this medication.
Document emailed within 1 workday
Related Documents
Bhatia, R.; Munthe, H.A.; Verfaillie, C.M. 1998: Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors Leukemia 12(11): 1708-1717Ohno, R. 2001: Treatment of chronic myelogenous leukemia with tyrosine kinase inhibitor Nihon Rinsho. Japanese Journal of Clinical Medicine 59(12): 2389-2394
Nagar, B. 2007: c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571) Journal of Nutrition 137(6 Suppl 1): 1518s-1523s; Discussion 1548s
Clark, R.H.; Taylor, L.L.; Wells, R.J. 1984: Congenital juvenile chronic myelogenous leukemia: case report and review Pediatrics 73(3): 324-326
Verstappen, M.C.H.M.; Mattijssen, V.; van der Reijden, B.A.; van der Heijden, A.J.P.; Wahab, P.J.; de Vries, R.A. 2006: A man with oral ulcers caused by hypereosinophilic syndrome and a good response to the tyrosine-kinase inhibitor imatinib Nederlands Tijdschrift Voor Geneeskunde 150(21): 1188-1192
Dunphy, C.H.; Petruska, P.J.; Martin, T.W. 1993: Demonstration of coexistent B-cell lymphoma and therapy-related acute myelogenous leukemia in lymph nodes by flow cytometry and immunohistochemistry. Case report and review of the literature Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology Inc 6(4): 500-504
Dika, E.; Barisani, A.; Vaccari, S.; Fanti, P.A.; Ismaili, A.; Patrizi, A. 2013: Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia Journal of Drugs in Dermatology: Jdd 12(5): 512-513
Chang, H.; Shih, L-Yung. 2008: Imatinib-induced tumor lysis syndrome: report of a case and review of the literature Chang Gung Medical Journal 31(5): 510-514
Chang, M-Wei.; Tang, C-Chih.; Chang, S-Shin. 2003: Priapism--a rare presentation in chronic myeloid leukemia: case report and review of the literature Chang Gung Medical Journal 26(4): 288-292
Usman, M.; Kakepoto, G.N.; Adil, S.N.; Sajid, R.; Arain, S.; Khurshid, M. 2004: Hematologic and cytogenetic findings in eleven chronic myelogenous leukemia patients treated with imatinib mesylate at a tertiary care hospital Jpma. Journal of the Pakistan Medical Association 54(1): 17-20
Bagadi, S.; Saikia, T.; Pany, A.; Das, B. 2011: Analysis of ABL Kinase Domain Mutations Conferring Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Cases from India Clinical Laboratory 57(7-8): 619-623
Weisser, M.; Tischer, J.; Schnittger, S.; Schoch, C.; Ledderose, G.; Kolb, H.Jochem. 2006: A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation Haematologica 91(5): 663-666
Gaertner, E.M.; Switlyk, S.A. 2012: Cutaneous granulomatous vasculitis associated with chronic lymphocytic leukemia: case report and review of literature of a rare entity Dermatology Online Journal 18(3): 12
Heinzl, S. 2002: The tyrosine kinase antagonist imatinib mesylate Medizinische Monatsschrift für Pharmazeuten 25(1): 4-7
Mahon, F.-X. 2019: When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia? Clinical Advances in Hematology and Oncology: H&o 17(2): 101-103
Dou, X.L.; Wang, S.S.; Fang, J.L.; Yu, L.; Ren, X.; Huang, X.J.; Jiang, Q. 2018: Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia Zhonghua Nei Ke Za Zhi 57(9): 649-655
Szczylik, C.; Skórski, T.; Malaguarnera, L.; Hetman, J.; Chen, S.T.; Calabretta, B. 1996: Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides Folia Histochemica et Cytobiologica 34(3-4): 129-134
Gelderblom, H.; Hogendoorn, P.C.; van der Graaf, W.T.; Verweij, J. 2003: Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor Nederlands Tijdschrift Voor Geneeskunde 147(42): 2051-2055
Chhabra, S.; Jain, S.; Fowler, A.; Sedov, V.; Neppalli, A.K.; Schandl, C.A.; Lazarchick, J. 2017: IgM Myeloma with Plasma Cell Leukemia: Case Report and Literature Review Annals of Clinical and Laboratory Science 47(5): 611-619
Martins, M.Domingues.; Anunciato de Jesus, L.; Fernandes, K.Porta.Santos.; Bussadori, S.Kalil.; Taghloubi, S.Ahmad.; Martins, M.Antonio.Trevizani. 2009: Intra-oral schwannoma: case report and literature review Indian Journal of Dental Research: Official Publication of Indian Society for Dental Research 20(1): 121-125